Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): A southwest oncology group study

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5418-5424

  Le, Quynh Thu ^a,i   McCoy, Jason ^b   Williamson, Stephen ^c   Ryu, Janice ^d   Gaspar, Laurie E ^e   Edelman, Martin J ^f   Dakhil, Shaker R ^g   Sides, Stanley D ^h   Crowley, John J ^b   Gandara, David R ^d  

^a STANFORD UNIVERSITY   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^g WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^h St Louis Comm Clin Oncol Program   (United States)

ⁱ Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; TIRAPAZAMINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; DRUG RESPONSE; DYSPHASIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGITIS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TRIAZINES; VOMITING;

EID: 4143091521     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0436     Document Type: Article

References (49)

1. Armstrong JG. Tumors of the lung and mediastinum. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology, Vol. 1. Philadelphia: W. B. Saunders Company, 1998. pp. 567-600.
2. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
3. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5.
4. Murray N, Coy P, Pater J. Importance of timing for thoracic irradiation in the combined modality treatment of limited small-cell carcinoma of the lung. J Clin Oncol 1993;11:336-44.
5. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054-60.
6. Bunn PA, Jr, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol 1997;24(2Suppl 7):S69-74.
7. McCracken JD, Janaki LM, Crowley JJ. Concurrent chemotherapy/radiotherapy for limited small cell lung carcinoma. J Clin Oncol 1990; 8:892.
8. Edelman MJ, Gandara DR. Small cell lung cancer: current status of new chemotherapeutic agents. Crit Rev Oncol Hematol 1998;27:211-20.
9. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
10. Movsas B, Moughan J, Komaki R, et al. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 2003;21:4553-9.
11. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58: 1408-16.
12. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57:39-43.
13. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.
14. Brizel DM, Scully SP, Harrelson JM. Tumor oxygenation predicts for likelihood of distant metastasis in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
15. Urtasun RC, Parliament MB, McEwan AJ, et al. Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. Br J Cancer Suppl 1996;27:S209-12.
16. Parliament MB, Chapman JD, Urtasun RC, et al. Non-invasive assessment of human tumour hypoxia with 1231-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90-5.
17. Suzuki Y, Hasegawa M, Hayakawa K, Mitsuhashi N, Niibe H. In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer. Anticancer Res 1999;19: 3993-4000.
18. Brown JM, Sim BG. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 1996;6:22-6.
19. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 1997;39:361-6.
20. Weitman S, Mangold G, Marty J, et al. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 1999;43:402-8.
21. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42.
22. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48:791-5.
23. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1998;16:3524-7.
24. Shulman LN, Buswell L, Riese N, et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 1999;44:349-53.
25. Senan S, Rampling R, Graham MA, et al. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clinical Cancer Res 1997;3:31-8.
26. Thomas CR Jr, Giroux DJ, Stelzer KJ, et al. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229). Int J Radiat Oncol Biol Phys 1998;40:1039-47.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
28. Turrisi AT, Sherman CA. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer 2002;38:279-91.
29. Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000;117(4 Suppl 1):S156-62.
30. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53:4633-6.
31. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000;18:1351-9.
32. Shepherd F, Koschel G, von Pawel J, et al. Comparison of Tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international phase III CATAPULT II Trial. Lung Cancer 2000;29(Suppl 1):S28.
33. Williamson SK, Crowley JJ, Lara PN Jr, et al. S0003: paclitaxel/ carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Oncol 2003;22:622.
34. Galvin IV, Lara PN Jr, Le QT, et al. Hypoxia-induced proteins in plasma of patients on the Southwest Oncology Group (SWOG) S0003 trial in advanced non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2003;22:667.
35. Edelman MJ, Chansky K, Gaspar LE, et al. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/ carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol 2004;22:127-32.
36. Cobb LM, Nolan J, O'Neill P. Microscopic distribution of misonidazole in mouse tissues. Br J Cancer 1989;59:12-6.
37. Parliament MB, Wiebe LI, Franko AJ. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br J Cancer 1992;66:1103-8.
38. Antonadou D, Throuvalas N, Petridis A, Bolanos N, Sagriotis A, Synodinou M. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:402-8.
39. Johnson DH, Bass D, Einhorn LH, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993;11:1223-9.
40. Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys 1989;17:307-10.
41. Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528-36.
42. Choi NC, Herndon J, Rosenman J, et al Long term survival data from CALGB 8837: radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC). Possible radiation dose-survival relationship. Proc Am Soc Clin Oncol 2002;21:298a.
43. Roof KS, Fidias P, Lynch TJ, Ancukiewicz M, Choi NC. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:701-8.
44. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-60.
45. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-10.
46. Peters LJ. Targeting hypoxia in head and neck cancer. Acta Oncol 2001;40:937-40.
47. Lara PN Jr, Frankel P, Mack PC, et al. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a California Cancer Consortium phase I and molecular correlative study. Clin Cancer Res 2003;9:4356-62.
48. Koong AC, Denko NC, Hudson KM, et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000;60:883-7.
49. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59-67.